Trials | Race | Regimens | Primary endpoint | Result of the trials | Conclusion of the trials | Reference |
---|---|---|---|---|---|---|
16968 | Whites | 5-FU/LV vs. CapeOX | 3-Year DFS rate | 66.5 vs. 70.9 % | Superiority of CapeOX to 5-FU/LV | [8] |
MOSAIC | Whites | LV5FU2 vs. FOLFOX4 | 3-Year DFS rate | 65.3 vs. 72.2 % | Superiority of FOLFOX4 to LV5FU2 | [9] |
INT 0089 | Whites | 5-FU/LV (RPMI) vs. 5-FU/LV (Mayo) | 5-Year OS rate | 66.0 vs. 66.0 % | Non-inferiority of 5-FU/LV (RPMI) to 5-FU/LV (Mayo) | [20] |
GERCOR C96.1 | Whites | 5-FU/LV (Mayo) vs. LV5FU2 | 6-Year DFS rate | 65.0 vs. 66.0 % | Non-inferiority of 5-FU/LV (Mayo) to LV5FU2 | [21] |
Japanese | FOLFOX4 vs. mFOLFOX6 | Response rate | 53.7 vs. 46.6 % | Non-inferiority of mFOLFOX6 to FOLFOX4 | [10]a | |
NSABP C-06 | Whites | 5-FU/LV vs. UFT/LV | 5-Year OS rate | 71.5 vs. 69.6 % | Non-inferiority of UFT/LV to 5-FU/LV | [12] |
X-ACT | Whites | 5-FU/LV vs. capecitabine | 3-Year DFS rate | 60.6 vs. 64.2 % | Non-inferiority of capecitabine to 5-FU/LV | [13] |
ACTS-CC | Japanese | UFT/LV vs. S-1 | 3-Year DFS rate | 72.5 vs. 75.5 % | Non-inferiority of S-1 to UFT/LV | [14] |